KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Gains from Sales and Divestitures: 2018-2020

Historic Gains from Sales and Divestitures for Aquestive Therapeutics (AQST) over the last 3 years, with Dec 2020 value amounting to $64,000.

  • Aquestive Therapeutics' Gains from Sales and Divestitures fell 48.80% to $64,000 in Q4 2020 from the same period last year, while for Dec 2020 it was $64,000, marking a year-over-year decrease of 48.80%. This contributed to the annual value of $64,000 for FY2020, which is 48.80% down from last year.
  • Latest data reveals that Aquestive Therapeutics reported Gains from Sales and Divestitures of $64,000 as of FY2020, which was down 48.80% from $125,000 recorded in FY2019.
  • In the past 5 years, Aquestive Therapeutics' Gains from Sales and Divestitures registered a high of $125,000 during FY2019, and its lowest value of $60,000 during FY2018.
  • Over the past 3 years, Aquestive Therapeutics' median Gains from Sales and Divestitures value was $64,000 (recorded in 2020), while the average stood at $83,000.
  • In the last 5 years, Aquestive Therapeutics' Gains from Sales and Divestitures surged by 108.33% in 2019 and then tumbled by 48.80% in 2020.
  • Yearly analysis of 3 years shows Aquestive Therapeutics' Gains from Sales and Divestitures stood at $60,000 in 2018, then surged by 108.33% to $125,000 in 2019, then crashed by 48.80% to $64,000 in 2020.